Ocular Therapeutix (OCUL) Preferred Stock Liabilities (2013 - 2014)
Ocular Therapeutix's quarterly Preferred Stock Liabilities came in at $74.4 million in Q2 2014, little changed quarter-over-quarter from $74.3 million in Q4 2013.
Ocular Therapeutix has reported Preferred Stock Liabilities for 2 years, with the latest figure at $74.4 million in Q2 2014.
- For the quarter ending Q2 2014, Preferred Stock Liabilities changed N/A year-over-year to $74.4 million; the trailing twelve-month figure through Jun 2014 stood at $74.4 million (changed N/A YoY), and the FY2013 full-year result was $74.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2014 stood at $74.4 million, roughly flat from $74.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $74.4 million in Q2 2014, with the low at $74.3 million in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 74.36 Mn |
| Dec 31, 2013 | 74.34 Mn |